跳至主要内容
临床试验/EUCTR2013-002822-21-GB
EUCTR2013-002822-21-GB进行中(未招募)1 期

The early use of Antibiotics for at Risk CHildren with InfluEnza in primary care (ARCHIE): a double-blind randomised placebo-controlled trial - The early use of Antibiotics in at Risk Children with InfluEnza-ARCHIE

niversity of Oxford0 个研究点目标入组 650 人开始时间: 2013年10月10日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
650

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • Aged 6 months to 12 years inclusive.
  • In ‘at risk’ category*.
  • Presenting with influenza-like illness (i.e. cough and fever**) during influenza season.
  • Presenting within 5 days of symptom onset.
  • Permanently registered at a general practice in England.
  • Parent /guardian able to complete study diary and questionnaires.
  • *’At risk’ categories:
  • The following ‘at risk’ categories are intended to guide clinicians in identifying which children are likely to be at greater risk of influenza-related clinical deterioration or complications. However, healthcare professionals should also use their own clinical judgement to identify ‘at risk’ children and may discuss children whom they think may be ‘at risk’ with a medically qualified member of the research team.
  • Respiratory
  • Asthma requiring continuous or repeated use of controller therapy (e.g. inhaled steroids, leukotriene receptor antagonists, long-acting beta agonists, systemic steroids)
  • Admitted to hospital with exacerbation of asthma within the last 12 months.
  • Admitted to hospital with bronchiolitis within the last 12 months.
  • Recurrent viral wheeze (3 or more episodes within the last 12 months).
  • Bronchopulmonary dysplasia.
  • Congenital heart disease being actively managed or monitored by cardiology team.
  • Chronic heart failure being actively managed or monitored by cardiology team.
  • Neurological
  • Chronic neurological or neuromuscular disorder which compromises respiratory function (e.g. cerebral palsy).
  • Chronic kidney disease defined as either of the following:
  • Impaired eGFR (estimated glomerular filtration rate) measurement within the last 12 months.
  • Known hereditary or structural kidney abnormality with or without impairment in eGFR.
  • Nephrotic syndrome.
  • Kidney transplantation.
  • Biliary atresia
  • Chronic hepatitis
  • Immunodeficiency
  • Asplenia or splenic dysfunction.
  • HIV infection.
  • Undergoing chemotherapy leading to immunosuppression.
  • Taking systemic steroids at a dose equivalent to prednisolone 20mg or more per day (any age) or >=1mg per kg per day (children under 20kg).
  • Diabetes mellitus (type 1 or type 2) or other metabolic condition.
  • Genetic abnormality (e.g. Down’s syndrome)
  • Sickle cell disease
  • Malignancy
  • Prematurity (born before 37 weeks gestation) in children aged 6 to 23 months.
  • Impaired eGFR is defined as an eGFR measurement of 59 ml/min/1.73m2 or less within the last 12 months before study entry. However, to enter the trial the following two conditions must also be satisfied: 1) eGFR >=30 ml/min/1.73m2 based on most recent measurement within the last 12 months; 2) no reason to suspect further deterioration in eGFR at time of study entry.
  • Children with mild or moderate liver disease may enter the trial. Children wi

排除标准

  • Known contraindication to co-amoxiclav.
  • Child given antibiotics within the last 72 hours.
  • Child requires immediate antibiotics or hospital admission (clinician’s judgement).
  • Presence of any reason to prevent healthcare professional from obtaining high nasal swab.
  • Child with known cystic fibrosis.
  • Child previously entered into the ARCHIE study.
  • Child has been involved in another medicinal trial within the last 90 days.

研究者

相似试验

The early use of Antibiotics in at Risk CHildren... | 临床试验